MicroRNA-184 Deregulated by the MicroRNA-21 Promotes Tumor Malignancy and Poor Outcomes in Non-small Cell Lung Cancer via Targeting CDC25A and c-Myc

Lin, Tung-Yi; Lin, Pei-Ying; Cheng, Ya Wen; Wu, Tzu Chin; Chou, Ming Chih; Chen, Chih Yi; Lee, Huei

doi:10.1245/s10434-015-4595-z

Cited by 37 publications

(38 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…41 As suggested by various studies, miR-184 might be a useful diagnostic and therapeutic tool for malignant diseases. 38,39 However, to the best of our knowledge, ours is the first study to provide data about miR-184 expression in EC.…”

Section: Discussionmentioning

confidence: 92%

“…In the same way, miR-184 functions as a tumor suppressor in various cancers (renal carcinoma, 36 glioma, 37,38 non-small-cell lung cancer, 39 oral squamous cell carcinoma, 40 breast cancer 41 ) by repressing oncogenes such as TNFAIP2, 37 SND1, 38 CDC25A, c-MYC, 39 and regulating the AKT/mTORC1 pathway. 41 As suggested by various studies, miR-184 might be a useful diagnostic and therapeutic tool for malignant diseases.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Identification of microRNA expression profile related to lymph node status in women with early-stage grade 1–2 endometrial cancer

et al. 2016

View full text Add to dashboard Cite

Conventional methods used for histologic classification and grading of endometrial cancer (EC) are not sufficient to predict lymph node metastases. microRNA signatures have recently been related to EC pathologic characteristics or prognosis. The aim of this study was to evaluate whether microRNA profiles of grade 1-2 endometrioid adenocarcinomas can be related to nodal status and used as a tool to adapt surgical staging in early-stage EC. microRNA expression was assessed in nine formalin-fixed paraffin-embedded (FFPE) EC primary tumors with positive lymph node and in 27 FFPE EC primary tumors with negative lymph node, matched for grade, stage, and lymphovascular space involvement status. A microarray analysis showed that there was more than a twofold significant difference in the expression of 12 microRNAs between the two groups. A quantitative reverse transcriptase-PCR assay was used to confirm these results: the expression levels of five microRNAs (microRNA-34c-5p, -375, -184, -34c-3p, and -34b-5p) were significantly lower in the EC primary tumor with positive lymph node compared with those with negative lymph node. A minimal P-value approach revealed that women with a microRNA-375-fold change o 0.30 were more likely to have positive lymph node (n = 8; 53.3%) compared with those with a microRNA-375-fold change 40.30 (n = 1; 4.8%), P = 0.001. Furthermore, women with a microRNA 184-fold change o0.30 were more likely to have positive lymph node (n = 6; 60.0%) compared with those with a microRNA 184-fold change 40.30 (n = 3; 11.5%), P = 0.006. This is the first study investigating the relative expression of mature microRNA genes in early-stage grade 1-2 EC primary tumors according to the nodal status. This microRNA expression profile provides a potential basis for further study of the microRNA function in EC and could be used as a diagnostic tool for nodal status.

show abstract

Section: Discussionmentioning

confidence: 92%

Section: Discussionmentioning

confidence: 99%

Identification of microRNA expression profile related to lymph node status in women with early-stage grade 1–2 endometrial cancer

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Furthermore, a low expression level of miR-184 may be a predictor of poor prognosis in patients with non-small cell lung cancer. Upregulation of miR-184 decreased cell proliferation and invasion by targeting cell division cycle 25A and c-Myc (31). In renal cell carcinoma, overexpression of miR-184 suppressed cell proliferation and migration, and enhanced cell apoptosis in vitro (28).…”

Section: Discussionmentioning

confidence: 98%

“…It has been identified to be upregulated in hepatocellular carcinoma (26) and squamous cell carcinoma of the tongue (27). However, downregulation of miR-184 has also been identified in various types of human cancer, including renal cell carcinoma (28), nasopharyngeal carcinoma (29), neuroblastoma (30), non-small cell lung cancer (31), glioma (32,33) and breast cancer (32). The contradictory results of these studies indicated that the expression levels of miR-184 in cancer exhibit tissue-specificity.…”

Section: Discussionmentioning

confidence: 99%

MicroRNA-184 inhibits cell proliferation and metastasis in human colorectal cancer by directly targeting IGF-1R

Liu

et al. 2017

Oncology Letters

View full text Add to dashboard Cite

Abstract. Colorectal cancer is currently the third most common cancer in males and the second in females worldwide. In spite of marked progress having been achieved in surgical resection, radiotherapy and chemotherapy, the prognosis for patients with colorectal cancer remains poor. Previous studies have demonstrated that the abnormal expression of microRNAs contributed to human cancer carcinogenesis and progression, suggesting miRNAs as novel therapeutic targets in colorectal cancer. The aim of the present study was to investigate the expression, functions and underlying molecular mechanisms of microRNA-184 (miR-184) in colorectal cancer. The results identified that miR-184 was significantly downregulated in colorectal cancer tissues and cell lines. In vitro functional studies demonstrated that miR-184 significantly inhibited colorectal cancer cell proliferation, migration and invasion. Notably, insulin-like growth factor 1 receptor (IGF-1R) was identified as a direct target of miR-184 in colorectal cancer. Furthermore, the functions of IGF-1R small interfering RNA were similar to those induced by miR-184 in colorectal cancer, suggesting IGF-1R as a functional target of miR-184 in colorectal cancer. The results of the present study indicated that miR-184 may be a novel therapeutic strategy regimen of targeted therapy for colorectal cancer.

show abstract

“…MiR-184 directly targets c-Myc to suppress cell growth in non-small cell lung cancer (NSCLC) [4]. We recently reported that a decrease in miR-184 by miR-21 promotes tumor malignancy and poor outcomes in non-small cell lung cancer (NSCLC) via targeting CDC25A and c-Myc [5]. Therefore, miR-184 might play a tumor suppressor role in NSCLC.…”

Section: Introductionmentioning

confidence: 99%

Reduction of microRNA-184 by E6 oncoprotein confers cisplatin resistance in lung cancer via increasing Bcl-2

et al. 2016

Self Cite

View full text Add to dashboard Cite

MicroRNA-184 suppresses cell growth and survival via targeting c-Myc and Bcl- 2. We recently reported that miR-184 promotes tumor progression in non-small cell lung cancer via targeting CDC25A and c-Myc. We here hypothesized that miR-184 could be down-regulated by E6 oncoprotein to confer cisplatin resistance in NSCLC. Human papillomavirus (HPV) 16-positive lung cancer TL-1 and cervical cancer SiHa cells compared with HPV16-negative TL-10 and C33A cells were enrolled for E6 manipulation. MiR-184 expression levels were increased by E6-knockdown in TL-1 and SiHa cells, but decreased by E6-overexpression in TL-10 and C33A cells. The MTT assay showed that the inhibition concentration of cisplatin yielding for 50% cell viability was dependent on miR-184 levels. Bcl-2 de-targeted by E6-mediated miR- 184 reduction was responsible for cisplatin resistance. Luciferase reporter assay and real- time PCR analysis indicated that the miR-184 promoter activity and its expression were modulated by E6 and/or p53 manipulation. Chromatin immunoprecipitation (ChIP) assay confirmed that p53 was bound onto the miR-184 promoter and its binding activity was modulated by E6 and/or p53 manipulation. Among patients, high miR184 and high Bcl-2 mRNA expression was more commonly occurred in E6- positive tumors than in E6-negative tumors. Fifty-nine out of 136 patients receiving cisplatin-based chemotherapy were available for the retrospective study. Patients with low-mR-184, E6-positive, high-Bcl-2 tumors, and both combinations were more prevalently occurred unfavorable response to cisplatin-based chemotherapy than their counterparts. In conclusion, a decrease in miR-184 level by E6 oncoprotein may predict unfavorable response to cisplatin-based chemotherapy in HPV-infected NSCLC patients via increasing Bcl-2 expression.

show abstract

MicroRNA-184 Deregulated by the MicroRNA-21 Promotes Tumor Malignancy and Poor Outcomes in Non-small Cell Lung Cancer via Targeting CDC25A and c-Myc

Abstract: MiR-184 as a tumor suppressor miR inhibits cell proliferation and invasion capability via targeting CDC25A and c-Myc. Low miR-184 level may predict worse prognosis in NSCLC patients.

Cited by 37 publications

References 17 publications

Identification of microRNA expression profile related to lymph node status in women with early-stage grade 1–2 endometrial cancer

Identification of microRNA expression profile related to lymph node status in women with early-stage grade 1–2 endometrial cancer

MicroRNA-184 inhibits cell proliferation and metastasis in human colorectal cancer by directly targeting IGF-1R

Reduction of microRNA-184 by E6 oncoprotein confers cisplatin resistance in lung cancer via increasing Bcl-2

Contact Info

Product

Resources

About